SWK Holdings Corporation (SWKH)
- Previous Close
17.25 - Open
16.78 - Bid --
- Ask --
- Day's Range
16.78 - 17.27 - 52 Week Range
15.26 - 18.75 - Volume
7,090 - Avg. Volume
11,009 - Market Cap (intraday)
215.825M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
13.82 - EPS (TTM)
1.25 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.
www.swkhold.com23
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SWKH
Performance Overview: SWKH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SWKH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SWKH
Valuation Measures
Market Cap
215.01M
Enterprise Value
253.64M
Trailing P/E
13.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.78
Price/Book (mrq)
0.77
Enterprise Value/Revenue
6.72
Enterprise Value/EBITDA
13.09
Financial Highlights
Profitability and Income Statement
Profit Margin
46.73%
Return on Assets (ttm)
5.01%
Return on Equity (ttm)
5.67%
Revenue (ttm)
34M
Net Income Avi to Common (ttm)
15.89M
Diluted EPS (ttm)
1.25
Balance Sheet and Cash Flow
Total Cash (mrq)
6.26M
Total Debt/Equity (mrq)
4.41%
Levered Free Cash Flow (ttm)
--